Replies to post #54021 on Therapeutic Solutions International Inc (TSOI)

[centsability4me]

The ApoptoCyte procedure was developed during experiments with the JadiCell™ mesenchymal stem cell which the Company has licensed for used in Lung Pathology, Chronic Traumatic Encephalopathy (CTE), and Traumatic Brain Injury (TBI). The FDA has cleared a Phase III clinical trial for the JadiCell product in lung failure due to Covid-19. Use of the JadiCell for CTE is subject of a filed IND #27377 for which the Company is in the process of responding to FDA questions.

March 07, 2022

https://www.businesswire.com/news/home/20220307005467/en/Therapeutic-Solutions-International-Announces-ApoptoCyte-Procedure-for-Enhancing-Stem-Cell-Activity